Flow cytometric analysis of FMC63 expression on CAR (FMC63 scFv) transfected Jurkat (human T cell leukemia T lymphocyte). CAR (FMC63 scFv) transfected Jurkat were stained with PE Rabbit IgG Isotype Control (left panel) or SDT PE Rabbit Anti-FMC63 Antibody (right panel) at 1.25 μl/test. Flow cytometry and data analysis were performed using BD FACSymphony™ A1 and FlowJo™ software.
Anti-FMC63 Recombinant Rabbit mAb (PE Conjugate) (S-2163-30)
Anti-FMC63 Recombinant Rabbit mAb (PE Conjugate) (S-2163-30)
Price:
Regular price
$80 USD
Regular price
Sale price
$80 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | FMC63 scFv |
| Immunogen | Recombinant Protein |
| Clone Number | S-2163-30 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | FCM |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | PE |
| Physical Appearance | Liquid |
| Storage Buffer | PBS, 1% BSA, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 1.25μl per million cells in 100μl volume | Species independent |
Background
FMC63 scFv (single-chain variable fragment) is a recombinant protein derived from the variable regions (VH and VL) of the anti-CD19 monoclonal antibody FMC63, linked by a flexible peptide spacer (e.g., (Gly₄Ser)₃). It specifically binds to the B-cell surface antigen CD19 with high affinity (KD ~1-10 nM) and is a key targeting component in FDA-approved CAR-T therapies, such as Kymriah®. The humanized FMC63 scFv retains potent antigen recognition while minimizing immunogenicity, making it highly effective in treating B-cell malignancies, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). Ongoing research focuses on optimizing its affinity, stability, and functionality to enhance the safety and efficacy of CAR-T cell therapies.
Picture
Picture
FC
